A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Clinical trial NCT06742723 · RECRUITING
Trial details
- NCT number
- NCT06742723
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-03
- Primary completion
- 2029-12-18
- Enrollment
- 5000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.